Menu
Search
|

Menu

Close
X

Novan Inc NOVN.OQ (NASDAQ Stock Exchange Global Market)

3.35 USD
-- (--)
As of Feb 22
chart
Previous Close 3.35
Open --
Volume --
3m Avg Volume 23,227
Today’s High --
Today’s Low --
52 Week High 8.19
52 Week Low 2.85
Shares Outstanding (mil) 25.99
Market Capitalization (mil) 87.06
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY17
2
FY16
0
FY15
0
EPS (USD)
FY17
-1.811
FY16
-3.448
FY15
-1.048
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.59
Price to Sales (TTM)
vs sector
57.32
8.08
Price to Book (MRQ)
vs sector
10.30
5.24
Price to Cash Flow (TTM)
vs sector
--
25.98
Total Debt to Equity (MRQ)
vs sector
154.45
15.60
LT Debt to Equity (MRQ)
vs sector
154.24
12.18
Return on Investment (TTM)
vs sector
-116.87
13.67
Return on Equity (TTM)
vs sector
-172.78
15.40

EXECUTIVE LEADERSHIP

Robert Ingram
Independent Chairman of the Board, Since 2011
Salary: --
Bonus: --
Nathan Stasko
President, Chief Scientific Officer, Director, Since 2017
Salary: $340,000.00
Bonus: $174,000.00
G. Kelly Martin
Interim Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Jeff Hunter
Chief Business Officer, Interim Chief Financial Officer and Principal Financial and Accounting Officer, Since 2018
Salary: --
Bonus: --
Stanley Hollenbach
Senior Vice President - Research and Development, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

4105 Hopson Rd
MORRISVILLE   NC   27560-9018

Phone: +1919.4858080

Novan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company's formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate.

SPONSORED STORIES